HIV Nursing Matters, Volume 10- A focus on dolutegravir

The Southern African HIV Clinicians Society

This edition of HIV Nursing Matters introduces one of the most exciting and highly anticipated antiretroviral (ARV) drugs to enter the HIV treatment space. Dolutegravir (DTG) – a drug with low cost, convenient dosing schedule, high potency, rapid virucidal activity, low toxicity, high genetic barrier to resistance, limited drug-drug interactions, and availability in single-tablet regimen – appears to tick virtually all the boxes of an ideal ARV. However, concerns about teratogenicity emerged just prior to its anticipated entry into the South African formulary in 2018. This delayed its introduction into the South African public healthcare system because of the layer of complexity this imposed on mass rollout of this new ‘wonder drug’. Finally, this drug is poised to make an entry into the SA public health sector, come 2020. This edition of HIV Nursing Matters provides an in-depth overview of all relevant characteristics of DTG by experts in the field. The issue covers the mechanism of action, advantages of its use, role in treatment-naïve and -experienced subjects, risks associated with its use in situations where supporting drugs in the regimen are ineffective (functional monotherapy), side-effects of the drug, common drug interactions, impact on liver and renal function, use in the face of renal and liver dysfunction, and its use in women of child-bearing age and pregnancy. The issue ends with a most pertinent piece on the impact of drug stock-outs, a challenging reality of our fragile healthcare system.

April 23, 2020
Year of publication
2019
Resource types
Reports and Fact sheets
Countries
Tags
dolutegravir, ARV

Similar Resources

The following abstract was presented as part of a poster dicussion session on viral reservoirs at the 9th IAS Conference on HIV Science (IAS 2017).

Antiretroviral therapy (ART) that enables suppression of HIV replication has been successfully rolled out at large scale to HIV-positive patients in low-income and middle-income countries.

This first volume of the 90-90-90 Compendium is targeted at a wide range of readers in South Africa, including community members and/or politicians with no medical background.

Initiation of antiretroviral therapy (ART) following diagnosis of HIV infection at birth is an emerging area of paediatric HIV care. We present outcomes of HIV-infected infants identified at birth at Rahima Moosa Mother and Child Hospital in Johannesburg, South Africa.

The amount of HIV in your body fluids is called your viral load. Effective HIV treatment (antiretroviral therapy) suppresses the amount of HIV in your body fluids to the point where standard tests are unable to detect any HIV, or can only find a tiny trace. Doctors call this ‘virological…

BACKGROUND:

Attrition along the HIV care continuum slows gains in mitigating the South African HIV epidemic. Understanding population-level gaps in HIV identification, linkage, retention in care and viral suppression is critical to target programming.

BACKGROUND:

The goal of virtual elimination of horizontal and mother-to-child HIV transmission in South Africa (SA) has been proposed, but there have been few systematic investigations of which interventions are likely to be most critical to reducing HIV incidence.

South Africa has the largest number of individuals living with HIV and the largest antiretroviral therapy (ART) programme worldwide. In September 2016, ART eligibility was extended to all 7.1 million HIV-positive South Africans.

Across sub-Saharan Africa, prevention of mother-to-child transmission services are encountering increasing numbers of women already established on antiretroviral therapy (ART) when entering antenatal care.

Depression is a leading cause of disability and may be associated with decreased adherence to ART. We sought to describe the prevalence of depressive symptoms and outcomes one year after screening among patients receiving ART at a large HIV Clinic in Johannesburg, South Africa.